{"id":"ceftriaxone-azithromycin-amoxicilline-clavulanate-clarithromycin","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Diarrhea"},{"rate":"3-10","effect":"Nausea"},{"rate":"2-8","effect":"Abdominal pain"},{"rate":"1-5","effect":"Rash"},{"rate":"1-5","effect":"Vomiting"},{"rate":"1-3","effect":"Allergic reaction"},{"rate":"0.1-1","effect":"QT prolongation (macrolides)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ceftriaxone, amoxicillin/clavulanate, and clarithromycin are bactericidal agents that inhibit bacterial peptidoglycan cross-linking in the cell wall. Azithromycin and clarithromycin are macrolides that inhibit bacterial protein synthesis by binding to the 50S ribosomal subunit. Clavulanate is a beta-lactamase inhibitor that protects amoxicillin from enzymatic degradation. Together, these agents provide broad-spectrum coverage against gram-positive and gram-negative bacteria.","oneSentence":"This is a combination of four beta-lactam and macrolide antibiotics that work by inhibiting bacterial cell wall synthesis and protein synthesis to kill or inhibit growth of susceptible bacteria.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:43:58.891Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections susceptible to beta-lactams and macrolides (respiratory tract infections, otitis media, sinusitis, skin infections)"},{"name":"Community-acquired pneumonia"},{"name":"Helicobacter pylori eradication (amoxicillin/clavulanate with clarithromycin)"}]},"trialDetails":[{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT00717561","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of IV/PO Moxifloxacin in Subjects With Community-acquired Pneumonia","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-02","conditions":"Pneumonia","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ceftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin","genericName":"Ceftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination of four beta-lactam and macrolide antibiotics that work by inhibiting bacterial cell wall synthesis and protein synthesis to kill or inhibit growth of susceptible bacteria. Used for Bacterial infections susceptible to beta-lactams and macrolides (respiratory tract infections, otitis media, sinusitis, skin infections), Community-acquired pneumonia, Helicobacter pylori eradication (amoxicillin/clavulanate with clarithromycin).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}